Gilead Sciences Dirección
Dirección controles de criterios 3/4
El CEO de Gilead Sciences' es Dan O'Day , nombrado en Mar 2019, tiene una permanencia de 5.08 años. compensación anual total es $22.61M, compuesta por 7.7% salario y 92.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.039% de las acciones de la empresa, por valor de $32.52M. La antigüedad media del equipo directivo y de la junta directiva es de 4.2 años y 6.3 años, respectivamente.
Información clave
Dan O'Day
Chief Executive Officer (CEO)
US$22.6m
Compensación total
| Porcentaje del salario del CEO | 7.7% |
| Permanencia del CEO | 5.2yrs |
| Participación del CEO | 0.04% |
| Permanencia media de la dirección | 4.3yrs |
| Promedio de permanencia en la Junta Directiva | 6yrs |
Actualizaciones recientes de la dirección
Recent updates
Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
May 23We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation
May 02
Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark
Apr 22Gilead Sciences: Some Signs Of An Impending Bottom
Apr 22Gilead Sciences: Realizing Financial Projections Is Key
Mar 20Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77
Mar 13Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution
Mar 01Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77
Feb 28We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated
Feb 15Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77
Feb 13Gilead Sciences: Cheap For A Reason
Feb 10Gilead Sciences: The Sky Is Not Falling
Feb 01Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?
Jan 15What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You
Dec 25These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well
Nov 17Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?
Oct 10We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt
Aug 11Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$485m |
| Dec 31 2023 | US$23m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$22m | US$2m | US$5b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$4b |
| Mar 31 2022 | n/a | n/a | US$5b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$5b |
| Mar 31 2021 | n/a | n/a | US$301m |
| Dec 31 2020 | US$19m | US$2m | US$123m |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | -US$257m |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$29m | US$1m | US$5b |
Compensación vs. Mercado: La compensación total de Dan($USD22.61M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD13.51M).
Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.
CEO
Dan O'Day (59 yo)
5.2yrs
Permanencia
US$22,607,690
Compensación
Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 5.2yrs | US$22.61m | 0.039% $ 32.9m | |
| Chief Financial Officer | 4.5yrs | US$8.11m | 0.011% $ 9.1m | |
| Executive VP of Corporate Affairs | 1.8yrs | US$5.27m | 0.0011% $ 954.5k | |
| Chief Commercial Officer | 4.8yrs | US$8.59m | 0.0095% $ 8.0m | |
| Chief Medical Officer | 4.5yrs | US$8.39m | 0.0077% $ 6.5m | |
| Senior VP | 1.2yrs | sin datos | 0.0026% $ 2.2m | |
| Vice President of Investor Relations | 3.3yrs | sin datos | sin datos | |
| Executive Vice President of Human Resources | 4.8yrs | sin datos | sin datos | |
| Senior Vice President of Research | 4.3yrs | sin datos | sin datos | |
| Senior Vice President of Commercial Operations of Australia | no data | sin datos | sin datos | |
| Executive Vice President of Research | 3.1yrs | sin datos | sin datos | |
| Senior Vice President & Therapeutic Area Head of Gilead Oncology | 2.8yrs | sin datos | sin datos |
4.3yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de GILD se considera experimentado (4.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 5.2yrs | US$22.61m | 0.039% $ 32.9m | |
| Lead Independent Director | 3.6yrs | US$444.92k | 0.00082% $ 692.6k | |
| Member of Scientific Advisory Board | no data | US$16.00k | sin datos | |
| Independent Director | 6.3yrs | US$429.92k | 0.0020% $ 1.7m | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 6yrs | US$414.92k | 0.0010% $ 870.0k | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 7.8yrs | US$434.92k | 0.00011% $ 92.9k | |
| Chairperson of Scientific Advisory Board | no data | sin datos | sin datos |
6.0yrs
Permanencia media
70yo
Promedio de edad
Junta con experiencia: La junta directiva de GILD se considera experimentada (6.3 años de antigüedad promedio).